secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bone Biologics Corp (BBLG)
CIK:        0001419554
Form:       8-K
Filed at:   2026-09-29T21:00:43+00:00
Accession:  0001493152-26-044889
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.07
LLM model:  deepseek-v4.1-flash:cloud@v2

Bone Biologics holders approve reverse split range of 1-for-2 to 1-for-10 and warrant-share issuance at annual meeting
--------------------------------------------------------------------------------

- Stockholders approved a charter amendment for a reverse split of 1-for-2 up to 1-for-10 at board discretion; vote 806,603 for vs 137,720 against.
- Approved Nasdaq Rule 5635(d) issuance of shares underlying warrants from the July 7, 2026 Securities Purchase Agreement and H.C. Wainwright engagement letter; 147,340 for, 42,233 against.
- Elected four directors — Bruce Stroever, Siddhesh Angle, Robert Gagnon and Philip Meikle — each with roughly 152,615-158,799 votes for and about 3,900 withheld.
- Ratified Weinberg & Company, P.A. as independent auditor for fiscal 2026 (898,011 for, 49,834 against); advisory say-on-pay passed 139,592 for vs 49,851 against.
- 2,011,057 shares were entitled to vote and 951,746 were present or by proxy (about 47%), with 758,866 broker non-votes on the contested proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419554/000149315226044889/0001493152-26-044889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419554/000149315226044889/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-044889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer